Stoke Therapeutics/STOK

$6.83

2.71%
-
1D1W1MYTD1YMAX

About Stoke Therapeutics

Stoke Therapeutics, Inc. is a biotechnology company focused on addressing the underlying causes of severe genetic diseases by upregulating protein expression with ribonucleic acid-based medicines. Using its Targeted Augmentation of Nuclear Gene Output (TANGO) approach, the Company is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both the occurrence of seizures and non-seizure comorbidities. Its STK-002 is a ASO in preclinical development for the treatment of Autosomal Dominant Optic Atrophy (ADOA). STK-002 is designed to upregulate OPA1 protein expression by leveraging the non-mutant (wild-type) copy of the OPA1 gene.

Ticker

STOK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Edward Kaye

Employees

117

Headquarters

Bedford, United States

STOK Metrics

BasicAdvanced
$265.24M
Market cap
-
P/E ratio
-$2.43
EPS
0.57
Beta
-
Dividend rate

What the Analysts think about STOK

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 7 analysts.
178.18% upside
High $35.00
Low $6.00
$6.83
Current price
$19.00
Average price target

STOK Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-742.42% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$3.3M
-237.5%
Net income
$-24.5M
-19.93%
Profit margin
-742.42%
-158.23%

STOK Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 12.41%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.65
-$0.53
-$0.69
-$0.55
-
Expected
-$0.70
-$0.70
-$0.64
-$0.63
-$0.63
Surprise
-7.41%
-23.88%
8.43%
-12.41%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Stoke Therapeutics stock

Buy or sell Stoke Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing